BioNTech (NASDAQ:BNTX) Price Target Cut to $106.00 by Analysts at Morgan Stanley

BioNTech (NASDAQ:BNTX) had its price objective cut by Morgan Stanley from $114.00 to $106.00 in a report released on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley‘s price objective would indicate a potential upside of 17.37% from the company’s previous close.

Several other research analysts have also recently weighed in on the company. Wells Fargo & Company decreased their price target on BioNTech from $140.00 to $125.00 and set an “overweight” rating for the company in a research note on Wednesday. Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Berenberg Bank set a $140.00 price target on BioNTech in a report on Wednesday, September 16th. UBS Group reaffirmed a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. Finally, Bank of America reissued a “buy” rating on shares of BioNTech in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and an average price target of $124.27.

BioNTech Stock Up 3.9%

Shares of BNTX stock traded up $3.39 during midday trading on Wednesday, reaching $90.31. 748,094 shares of the stock were exchanged, compared to its average volume of 1,091,199. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00. The firm has a market cap of $22.84 billion, a PE ratio of -11.54 and a beta of 1.28. The company’s 50 day moving average is $96.14 and its two-hundred day moving average is $96.99.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. During the same period in the prior year, the business posted ($1.60) EPS. The business’s quarterly revenue was down 59.5% compared to the same quarter last year. On average, equities research analysts predict that BioNTech will post -6.62 EPS for the current year.

Insider Activity

In other news, CEO Ugur Sahin sold 36,209 shares of the firm’s stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $95.37, for a total value of $3,453,252.33. Following the completion of the sale, the chief executive officer owned 36,209 shares in the company, valued at approximately $3,453,252.33. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 807,209 shares of company stock valued at $79,246,837. 19.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Flossbach Von Storch SE purchased a new stake in shares of BioNTech during the 2nd quarter worth $207,142,000. Bank of America Corp DE raised its stake in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after buying an additional 166,432 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in BioNTech by 79.7% in the third quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock worth $74,774,000 after acquiring an additional 337,412 shares in the last quarter. First Trust Advisors LP boosted its holdings in BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after acquiring an additional 451,124 shares in the last quarter. Finally, Candriam S.C.A. grew its stake in shares of BioNTech by 4.7% during the third quarter. Candriam S.C.A. now owns 520,972 shares of the company’s stock worth $51,399,000 after acquiring an additional 23,442 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech News Roundup

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Q3 results topped expectations: BioNTech reported earnings of $1.99 per share versus the $0.76 consensus and revenue of $1.49 billion versus $1.17 billion expected. The company also raised its 2026 revenue guidance to €1.7–€1.9 billion. Article: BioNTech beats third-quarter forecasts and raises revenue guidance despite pipeline setbacks
• Positive Sentiment: Oncology data and upcoming catalysts: BioNTech reported promising gotistobart results in previously treated squamous lung cancer and expects an interim analysis before year-end. It is also advancing pumitamig combination trials. These programs could support its longer-term shift toward oncology. Article: BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
• Neutral Sentiment: Wells Fargo lowered its target but kept an Overweight rating: The firm cut its price target from $140 to $125, while its revised target still implies substantial upside from the share price cited in the report. Article: Wells Fargo & Company stock recommendations
• Negative Sentiment: Revenue remains pressured and pipeline risk persists: Q3 revenue fell 15.1% year over year amid lower COVID-19 vaccine demand. A bearish analysis cited ongoing cash burn, a narrowing pipeline, and increasing reliance on pumitamig and gotistobart, raising concerns about the sustainability of the oncology strategy. Article: BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.